Perspective Therapeutics, Inc. (CATX)
After hours:
| Previous close | 1.6000 |
| Open | 1.5800 |
| Bid | 1.5800 x 4000 |
| Ask | 1.6000 x 1200 |
| Day's range | 1.5311 - 1.6200 |
| 52-week range | 0.2100 - 1.7700 |
| Volume | |
| Avg. volume | 4,281,280 |
| Market cap | 927.327M |
| Beta (5Y monthly) | 1.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1400 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.57 |
GlobeNewswirePerspective Therapeutics to Participate at Upcoming April Investor Conferences
SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced it will participate in two investor conferences in April. Thijs Spoor, Chief Executive Officer, will be participating in a panel discussion titled Radiopharmaceuticals: Energizing Disruption in Therapeutics, at the Goldman Sachs Third Annu
GuruFocus.comPerspective Therapeutics Inc (CATX) Reports Fiscal Year 2023 Financial Results
Significant R&D Investments Lead to Increased Losses Despite Revenue Gains from Grants
- GlobeNewswire
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- Perspective, Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023. “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha
